Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results